T1	intervention 34 47	pegfilgrastim
T2	condition 57 76	febrile neutropenia
T3	control 359 366	placebo
T4	outcome-Measure 503 556	percentage of patients developing febrile neutropenia
T5	outcome-Measure 716 796	incidence of hospitalizations associated with a diagnosis of febrile neutropenia
T7	outcome-Measure 873 926	ability to maintain planned chemotherapy dose on time
T8	No-of-participants 1027 1052	Nine hundred twenty-eight
T9	control-participants 1084 1087	465
T10	intervention-participants 1111 1114	463
T11	outcome 1205 1237	incidence of febrile neutropenia
T12	intervention-value 1239 1241	1%
T13	control-value 1244 1247	17%
T14	outcome 1274 1317	febrile neutropenia-related hospitalization
T15	intervention-value 1319 1321	1%
T16	control-value 1324 1327	14%
T17	outcome 1358 1383	use of IV anti-infectives
T6	outcome-Measure 798 830	intravenous (IV) anti-infectives
T18	intervention-value 1385 1387	2%
T19	control-value 1390 1393	10%
T20	outcome 1424 1481	percentage of patients receiving the planned dose on time
T21	intervention-value 1580 1583	80%
T22	control-value 1588 1591	78%
